Please talk to your physician about these studies.
ACOSOG Z1031: A randomized phase III trial comparing 16-18 weeks of neoadjuvant Exemestane (25 mg daily), Letrozole (2.5 mg), or Anastrozole (1 mg) in postmenopausal women with clinical stage II and III estrogen receptor positive breast cancer.
ACOSOG Z1071 A Phase II study evaluating the role of sentinel lymph node surgery and axillary lymph node dissection following preoperative chemotherapy in women with node positive breast cancer (T0-4, N1-2, M0) at initial diagnosis.
Columbia Cognitive Trial: The effects of chemotherapy and estrogen on cognitive function in premenopausal women with breast cancer.
NCI 7868: Stage IIB-IIIC Breast Cancer R115777 + Taxol + Dose-Dense Doxorubicin & Cyclophos. estrogen and/or progesterone receptor +, Her2/neu -; no prior chemo, irradiation, or definitive therapeutic surgery
TAILORx (PACCT-1): Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment : tumor 1.1-5 cm, node negative: Oncotyping to select therapy, hormonal +/- chemo ER/PR +,HER2neu neg., candidate for adjuvant cytotoxic therapy + hormonal therapy
BETH (BCIRG 011) HER2-positive ,T1-3: docetaxel/carboplatin/trastuzumab (+or- Bevacizumab) FISH-positive and/or IHC 3+ must have total mastectomy or lumpectomy.
ECOG 5103 LN + & High Risk LN neg: Doxorubicin + Cyclophosphamide followed by Taxol with +/-Bev neg margin, HER2 + (3+ by IHC or FISH+) are NOT eligible.
Lilly S379 HER2-Neg, metastatic BC: A Phase 2 Study of Gemcitabine and Bevacizumab as First-Line Treatment in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer Previously Treated with Taxanes Must have received a taxane as neo-adjuvant and/or adjuvant therapy with a ≥12-month disease-free interval from completion of the therapy
Novartis CRAD001J2301 locally advanced or Metastatic: A Randomized Double-Blind, Study of Everolimus in Combination with Trastuzumab and Paclitaxel Her2+, Either no prior treatment w/Trastuzumab or if Tx then >12 mos prior to Rand, Prior Tx w/ Endocrine therapy allowed
Novartis CRAD001Y2301 Locally advanced or Metastatic: A Randomized Double-Blind, Study of Everolimus in Combination with Exemestane ER+, IHC 3+ staining or in situ hybridizatization positive, Clinical evidence of recurrence or progression on last systemic therapy prior to randomization
Lumpectomy and Brachytherapy as Salvage Treatment for Local Recurrences Following Breast Conservative Therapy
Accelerated Radiation Therapy in Early Stage Breast Cancer with an Infield Concomitant Boost using Intensity Modulated Radiation Therapy Techniques.
Mammary Ductoscopy and Intraductal Biopsy for Women at High Risk for Developing Breast Cancer, for Women Presenting with Spontaneous Nipple Discharge, and for Women Diagnosed with Breast Cancer Undergoing Surgery to the Contralateral Breast